undamentalytics Newsletter
Sign in

Adma Biologics, Inc. cash flow statement

In fiscal 2025, Adma Biologics, Inc.'s operations generated $50.4m of cash; it spent $22.6m on capital projects, leaving free cash flow of $27.8m. It returned $31.9m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−1−7−11−15−15−18−37−63−76−102−112−60911950137
Depreciation and amortisation0000002323568888
Stock-based pay0111212233356142023
Capital spending000200324131414582320
Free cash flow−1−7−11−17−15−18−40−65−80−115−126−73411028116
Free cash flow after stock pay−1−8−12−18−17−20−42−67−83−118−129−79−297894
Share buybacks00——————————0032187
Shares issued01727010133943481311216500——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ADMA vs HCMADMA vs KRYSADMA vs ARQT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Adma Biologics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Adma Biologics, Inc.